In October 2011, Macrocyclics was acquired by Avera Med, a subsidiary of renewable energy company Avera that is devoted on developing cancer therapeutics. Macrocyclics is a research & development company actively engaged in developing novel ligands for biomedicine and it is a trusted name in metal-ligand chelating technologies. The firm's primary technology platforms are high performance bifunctional ligands for targeting radionuclides to cancer cells and novel magnetic resonance imaging (MRI) agents. Macrocyclics has been actively developing new synthetic methodologies and cutting edge applications which have relied upon customized chelating agents since its inception. Macrocyclics has created an extensive IP portfolio and possesses world-recognized expertise in high performance chelation chemistries relevant to a broad spectrum of medical applications including bifunctional chelating agents, contrast enhancement media and molecular imaging. The firm's most recent technologies include novel techniques for rapid labeling of biomolecules with chelating agents, paramagnetic magnetization transfer and pH responsive contrast agents.
